On December 7, 2022 Accord Healthcare, Inc., a leading generic pharmaceutical company, reported it has added Bendamustine Lyo. Injection to its line of chemotherapy drugs (Press release, Accord Healthcare, DEC 7, 2022, View Source [SID1234624912]). Accord’s product is AP rated to Teva’s Treanda and is being offered in both 25-mg and 100-mg vials.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Bendamustine Lyo. Injection is in a class of medications called alkylating agents1. It works by killing existing cancer cells and limiting the growth of new cancer cells. Bendamustine is indicated for the treatment of adults with chronic lymphocytic leukemia (CLL) or indolent B-cell non-Hodgkin’s lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or rituximab containing regimen.
"Adding Bendamustine Lyo. Injection to our line of available chemotherapy drugs is an important step in continuing to make oncology therapies more accessible to those who need them," said Accord Healthcare President Jeff Hampton. "The availability of generics expands medication options for patients. When pharmacists have access to additional manufacturers, they are able to offer needed oncology products at a lower cost."
Important Safety Information:
Adverse reactions2 of Bendamustine Injection during infusion and within 24 hours post infusion may include nausea and fatigue (frequency >5%). Other adverse reactions can include myelosuppression, infections, anaphylaxis, tumor lysis syndrome, and skin reactions.
The most common non-hematologic adverse reactions for CLL are pyrexia, nausea, and vomiting. The most common non-hematologic adverse reactions for NHL (frequency ≥15%) are nausea, fatigue, vomiting, diarrhea, pyrexia, constipation, anorexia, cough, headache, weight decreased, dyspnea, rash, and stomatitis.2
Further information about safety and potential side effects can be found on the Products page at Accord Healthcare US.
Bendamustine was approved3 by the US Food and Drug Administration (FDA) for the treatment of chronic lymphocytic leukemia (CLL) in March 2008 and for the treatment of rituximab-refractory, indolent B-cell non-Hodgkin lymphoma (NHL) in October 2008.